Randomized trial of the ForeseeHome monitoring device for early detection of neovascular age-related macular degeneration. The HOme Monitoring of the Eye (HOME) study design - HOME Study report number 1

Contemporary Clinical Trials

Volumn 37, Issue 2, 2014, Pages 294-300

  Chew, Emily Y ^a   Clemons, Traci E ^b   Bressler, Susan B ^c   Elman, Michael J ^d   Danis, Ronald P ^e   Domalpally, Amitha ^e   Heier, Jeffrey S ^f   Kim, Judy E ^g   Garfinkel, Richard A ^h  

^a NATIONAL EYE INSTITUTE   (United States)

^b EMMES CORPORATION   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Elman Retina Group   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f Ophthalmic Consultant of Boston   (United States)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

^h Retina Group of Washington   (United States)

Author keywords

Age related macular degeneration; Best corrected visual acuity; Choroidal neovascularization; Controlled clinical trial; Home monitoring

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; BLINDNESS; CONTROLLED STUDY; DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HIGH RISK PATIENT; HOME MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPHTHALMOLOGICAL DIAGNOSTIC DEVICE; PATIENT CARE; PERIMETRY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; SELF MONITORING; SELF REPORT; SUBRETINAL NEOVASCULARIZATION; SYMPTOM; TELEMEDICINE; TELEMONITORING; VERY ELDERLY; VISION; VISUAL ACUITY; VISUAL IMPAIRMENT; AGING; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIAL; DEVICES; MACULAR DEGENERATION; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; RISK FACTOR;

AGED; AGED, 80 AND OVER; AGING; CHOROIDAL NEOVASCULARIZATION; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RESEARCH DESIGN; RISK FACTORS; TELEMEDICINE; VISUAL ACUITY; VISUAL FIELD TESTS;

EID: 84896749820     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2014.02.003     Document Type: Article

References (19)

1. Congdon N., O'Colmain B., Klaver C.C., Klein R., Munoz B., Friedman D.S., et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004, 122:477-485.
2. Friedman D.S., O'Colmain B.J., Muñoz B., Tomany S.C., McCarty C., de Jong P.T., et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004, 122:564-572.
3. Pascolini D., Mariotti S.P., Pokharel G.P., Pararajasegaram R., Etya'ale D., Negrel A.D., et al. 2002 global update of available data on visual impairment: a compilation of population-based prevalence studies. Ophthalmic Epidemiol 2004, 11:67-115.
4. Ferris F.L., Fine S.L., Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984, 102:1640-1642.
5. Brown D.M., Kaiser P.K., Michels M., Soubrane G., Heier J.S., Kim R.Y., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006, 355:1432-1444.
6. Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006, 355(14):1419-1431.
7. IVAN Study Investigators, Chakravarthy U., Harding S.P., Rogers C.A., Downes S.M., Lotery A.J., et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012, 119:1399-1411.
8. Heier J.S., Boyer D., Nguyen Q.D., Marcus D., Roth D.B., Yancopoulos G., et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology Jun 2011, 118(6):1098-1106.
9. Brown D.M., Heier J.S., Ciulla T., Benz M., Abraham P., Yancopoulos G., et al. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology 2011, 118:1089-1097.
10. CATT Research Group, Martin D.F., Maguire M.G., Ying G.S., Grunwald J.E., Fine S.L., et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med May 19 2011, 364(20):1897-908. [Epub 2011 Apr 28].
11. Ying G.S., Huang J., Maguire M.G., et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013, 120:122-129.
12. Kaiser P.K., Brown D.M., Zhang K., Hudson H.L., Holz F.G., Shapiro H., et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007, 144:850-857.
13. Boyer D.S., Antoszyk A.N., Awh C.C., Bhisitkul R.B., Shapiro H., Acharya N.R. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007, 114:246-252.
14. Fong D.S., Custis P., Howes J., Hsu J.W. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration. A multi-center, retrospective study. Ophthalmology 2010, 117(2):298-302.
15. Rauch R., Weingessel B., Maca S.M., Vecsei-Marlovits P.V. Time to first treatment - the significance of early treatment of exudative age-related macular degeneration. Retina 2012, 32:1260-1264.
16. Westheimer G. Editorial: visual acuity and hyperacuity. Invest Ophthalmol 1975, 145(8):570-572.
17. Loewenstein A., Ferencz J.R., Lang Y., Yeshurun I., Pollack A., Siegal R., et al. Toward earlier detection of choroidal neovascularization secondary to age-related macular degeneration: multicenter evaluation of a preferential hyperacuity perimeter designed as a home device. Retina 2010, 30:1058-1064.
18. Beck R.W., Moke P.S., Turpin A.H., Ferris F.L., San Giovanni J.P., Johnson C.A., et al. A computerized method of visual acuity testing: an adaptation of the Early Treatment Diabetic Retinopathy Study testing protocol. Am J Ophthalmol 2003, 135(2):194-205.
19. The AREDS2-HOME Study Research Group Randomized trial of a home monitoring system for early detection of choroidal neovascularization. Home Monitoring of the Eye (HOME) Study. Ophthalmology Nov 8 2013, [pii: S0161-6420(13)00952-4, Epub ahead of print]. 10.1016/j.ophtha.2013.10.027.